Sign In
Buy CSU
$33.30
+0 (+0%)
At Close: Jul 20, 2022
Constellation Software: The 'Star' Of The Canadian Software Show
01:51am, Wednesday, 12'th Feb 2025
Constellation Software excels in growth via acquisition in the vertical market software space, demonstrating consistent shareholder value creation over decades. CSU's decentralized operatorship and st
Constellation Software Inc. Announces Release Date for Fourth Quarter Results
04:55pm, Tuesday, 11'th Feb 2025
TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its fourth quarter results on March 7, 2025.
Constellation Software Inc. and Topicus.com Inc. announce execution of Treasury Shares Purchase Agreement
07:52pm, Tuesday, 04'th Feb 2025
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TOI.V) today announced that Topicus' subsidiary, Yukon Niebieski Kapital B.V. ("Yukon"), has ent
Constellation Software Inc. and Topicus.com Inc. announce execution of Treasury Shares Purchase Agreement
07:45pm, Tuesday, 04'th Feb 2025
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TOI.V) today announced that Topicus' subsidiary, Yukon Niebieski Kapital B.V. ("Yukon"), has ent
Constellation Software Inc. Announces Annual Interest Rate for Series 1 Debentures
05:13pm, Tuesday, 21'st Jan 2025
TORONTO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU, TSX: CSU.DB) (the “Company”) announced today that the interest rate applicable to the unsecured subordinated float
Topicus.com Inc. Reaches Agreement to acquire Cipal Schaubroeck in Belgium
08:03am, Tuesday, 14'th Jan 2025
TORONTO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus' subsidiary Total Specific Solutions (TSS) B.V. (“TSS�
Topicus.com Inc. Reaches Agreement to acquire Cipal Schaubroeck in Belgium
08:02am, Tuesday, 14'th Jan 2025
TORONTO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus' subsidiary Total Specific Solutions (TSS) B.V. (“TSS�
3 Tech Stocks to Buy Before Dec. 31st
10:04am, Wednesday, 18'th Dec 2024
Any investor who has been in the market for the past two decades has mostly benefited from being overweight technology stocks.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
12:59am, Friday, 15'th Nov 2024
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antih
Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2024 and Declares Quarterly Dividend
05:01pm, Friday, 08'th Nov 2024
TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the third quarter ended September
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market
03:14pm, Monday, 04'th Nov 2024
Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concer
Constellation Software Inc. Announces Release Date for Third Quarter Results
08:51pm, Tuesday, 15'th Oct 2024
TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its third quarter results on November 8, 2024.
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
01:05am, Wednesday, 11'th Sep 2024
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary an
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in
Constellation Software Inc. Announces Results for the Second Quarter Ended June 30, 2024 and Declares Quarterly Dividend
05:01pm, Friday, 09'th Aug 2024
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30,
